Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

Changing the standard of care for treating melanoma brain metastases.

Chapman PB.

Lancet Oncol. 2018 May;19(5):589-591. doi: 10.1016/S1470-2045(18)30187-6. Epub 2018 Mar 27. No abstract available.

PMID:
29602645
2.

Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).

Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, Piulats JM, Wolter P, Cocquyt V, Chmielowski B, Evans TRJ, Gastaud L, Linette G, Berking C, Schachter J, Rodrigues MJ, Shoushtari AN, Clemett D, Ghiorghiu D, Mariani G, Spratt S, Lovick S, Barker P, Kilgour E, Lai Z, Schwartz GK, Nathan P.

J Clin Oncol. 2018 Apr 20;36(12):1232-1239. doi: 10.1200/JCO.2017.74.1090. Epub 2018 Mar 12.

PMID:
29528792
3.

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.

Rosner S, Kwong E, Shoushtari AN, Friedman CF, Betof AS, Brady MS, Coit DG, Callahan MK, Wolchok JD, Chapman PB, Panageas KS, Postow MA.

Cancer Med. 2018 Mar;7(3):690-697. doi: 10.1002/cam4.1356. Epub 2018 Feb 22.

4.

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.

McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, Davies MA.

Lancet Oncol. 2018 Mar;19(3):310-322. doi: 10.1016/S1470-2045(18)30078-0. Epub 2018 Feb 12.

5.

Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation.

Momtaz P, Harding JJ, Ariyan C, Coit DG, Merghoub T, Gasmi B, You D, Viale A, Panageas KS, Samoila A, Postow MA, Wolchok JD, Chapman PB.

Oncotarget. 2017 Sep 16;8(62):105000-105010. doi: 10.18632/oncotarget.21072. eCollection 2017 Dec 1.

6.

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.

Chapman PB, Robert C, Larkin J, Haanen JB, Ribas A, Hogg D, Hamid O, Ascierto PA, Testori A, Lorigan PC, Dummer R, Sosman JA, Flaherty KT, Chang I, Coleman S, Caro I, Hauschild A, McArthur GA.

Ann Oncol. 2017 Oct 1;28(10):2581-2587. doi: 10.1093/annonc/mdx339.

7.

Time to publication of oncology trials and why some trials are never published.

Chapman PB, Liu NJ, Zhou Q, Iasonos A, Hanley S, Bosl GJ, Spriggs DR.

PLoS One. 2017 Sep 21;12(9):e0184025. doi: 10.1371/journal.pone.0184025. eCollection 2017.

8.

Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.

Algazi AP, Esteve-Puig R, Nosrati A, Hinds B, Hobbs-Muthukumar A, Nandoskar P, Ortiz-Urda S, Chapman PB, Daud A.

Pigment Cell Melanoma Res. 2018 Jan;31(1):110-114. doi: 10.1111/pcmr.12644. Epub 2017 Nov 2.

PMID:
28921907
9.

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.

Shoushtari AN, Friedman CF, Navid-Azarbaijani P, Postow MA, Callahan MK, Momtaz P, Panageas KS, Wolchok JD, Chapman PB.

JAMA Oncol. 2018 Jan 1;4(1):98-101. doi: 10.1001/jamaoncol.2017.2391.

10.

Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy.

Francis JH, Habib LA, Abramson DH, Yannuzzi LA, Heinemann M, Gounder MM, Grisham RN, Postow MA, Shoushtari AN, Chi P, Segal NH, Yaeger R, Ho AL, Chapman PB, Catalanotti F.

Ophthalmology. 2017 Dec;124(12):1788-1798. doi: 10.1016/j.ophtha.2017.05.038. Epub 2017 Jul 12.

PMID:
28709702
11.

A step forward for patients with NRAS-mutant melanoma.

Postow MA, Chapman PB.

Lancet Oncol. 2017 Apr;18(4):414-415. doi: 10.1016/S1470-2045(17)30172-9. Epub 2017 Mar 9. No abstract available.

12.

MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway.

Koetz-Ploch L, Hanniford D, Dolgalev I, Sokolova E, Zhong J, Díaz-Martínez M, Bernstein E, Darvishian F, Flaherty KT, Chapman PB, Tawbi H, Hernando E.

Pigment Cell Melanoma Res. 2017 May;30(3):328-338. doi: 10.1111/pcmr.12578. Epub 2017 Apr 19.

13.

Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab.

Friedman CF, Clark V, Raikhel AV, Barz T, Shoushtari AN, Momtaz P, Callahan MK, Wolchok JD, Chapman PB, Hellmann MD, Postow MA.

J Natl Cancer Inst. 2016 Dec 31;109(4). doi: 10.1093/jnci/djw260. Print 2017 Apr.

14.

Corrigendum: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET.

Peinado H, Alecˇković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, García-Santos G, Ghajar CM, Nitadori-Hoshino A, Hoffman C, Badal K, Garcia BA, Callahan MK, Yuan J, Martins VR, Skog J, Kaplan RN, Brady MS, Wolchok JD, Chapman PB, Kang Y, Bromberg J, Lyden D.

Nat Med. 2016 Dec 6;22(12):1502. doi: 10.1038/nm1216-1502b. No abstract available.

PMID:
27923027
15.

Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies.

Momtaz P, Pentsova E, Abdel-Wahab O, Diamond E, Hyman D, Merghoub T, You D, Gasmi B, Viale A, Chapman PB.

Oncotarget. 2016 Dec 20;7(51):85430-85436. doi: 10.18632/oncotarget.13397.

16.

Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients.

Lee AY, Droppelmann N, Panageas KS, Zhou Q, Ariyan CE, Brady MS, Chapman PB, Coit DG.

Ann Surg Oncol. 2017 Apr;24(4):939-946. doi: 10.1245/s10434-016-5642-0. Epub 2016 Nov 1.

17.

Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.

Shoushtari AN, Bluth MJ, Goldman DA, Bitas C, Lefkowitz RA, Postow MA, Munhoz RR, Buchar G, Hester RH, Romero JA, Fitzpatrick LJ, Weiser MR, Panageas KS, Wolchok JD, Chapman PB, Carvajal RD.

Melanoma Res. 2017 Feb;27(1):57-64. doi: 10.1097/CMR.0000000000000306.

18.

Discordance Between Cobas BRAF V600 Testing and VE1 Immunohistochemistry in a Melanoma Patient With Bone Marrow Metastases.

Rapisuwon S, Busam KJ, Parks K, Chapman PB, Lee E, Atkins MB.

Am J Dermatopathol. 2016 Sep;38(9):687-9. doi: 10.1097/DAD.0000000000000660.

19.

Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker.

Iasonos A, Chapman PB, Satagopan JM.

Clin Cancer Res. 2016 May 1;22(9):2114-20. doi: 10.1158/1078-0432.CCR-15-2517. Review.

20.

The Role of Neoadjuvant Trials in Drug Development for Solid Tumors.

Funt SA, Chapman PB.

Clin Cancer Res. 2016 May 15;22(10):2323-8. doi: 10.1158/1078-0432.CCR-15-1961. Epub 2016 Feb 3. Review.

21.

A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma.

Shoushtari AN, Ong LT, Schoder H, Singh-Kandah S, Abbate KT, Postow MA, Callahan MK, Wolchok J, Chapman PB, Panageas KS, Schwartz GK, Carvajal RD.

Melanoma Res. 2016 Jun;26(3):272-7. doi: 10.1097/CMR.0000000000000234.

22.

Reply to A. Indini et al.

Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D'Angelo SP, Woo KM, Panageas KS, Wolchok JD, Chapman PB.

J Clin Oncol. 2016 Mar 20;34(9):1018-9. doi: 10.1200/JCO.2015.65.7007. Epub 2016 Jan 19. No abstract available.

PMID:
26786917
23.

Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib.

Zabor EC, Heller G, Schwartz LH, Chapman PB.

Clin Cancer Res. 2016 Mar 15;22(6):1341-7. doi: 10.1158/1078-0432.CCR-15-1441. Epub 2015 Oct 21.

24.

Osteonecrosis of the jaw a new complication related to Ipilimumab.

Owosho AA, Scordo M, Yom SK, Randazzo J, Chapman PB, Huryn JM, Estilo CL.

Oral Oncol. 2015 Dec;51(12):e100-1. doi: 10.1016/j.oraloncology.2015.08.014. Epub 2015 Oct 5. No abstract available.

25.

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.

Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D'Angelo SP, Woo KM, Panageas KS, Wolchok JD, Chapman PB.

J Clin Oncol. 2015 Oct 1;33(28):3193-8. doi: 10.1200/JCO.2015.60.8448. Epub 2015 Aug 17.

26.

Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors.

Amaravadi RK, Hamilton KE, Ma X, Piao S, Portillo AD, Nathanson KL, Carlino MS, Long GV, Puzanov I, Xu X, Morrissette JJ, Tsai KY, Flaherty KT, Sosman JA, Goodman GR, McArthur GA, Rustgi AK, Metz DC, Schuchter LM, Chapman PB, Sepulveda AR.

Clin Cancer Res. 2015 Dec 1;21(23):5215-21. doi: 10.1158/1078-0432.CCR-15-0469. Epub 2015 Jul 22.

27.

Safety of Infusing Ipilimumab Over 30 Minutes.

Momtaz P, Park V, Panageas KS, Postow MA, Callahan M, Wolchok JD, Chapman PB.

J Clin Oncol. 2015 Oct 20;33(30):3454-8. doi: 10.1200/JCO.2015.61.0030. Epub 2015 Jun 29.

28.

Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team.

LoRusso PM, Boerner SA, Pilat MJ, Forman KM, Zuccaro CY, Kiefer JA, Liang WS, Hunsberger S, Redman BG, Markovic SN, Sekulic A, Bryce AH, Joseph RW, Cowey CL, Fecher LA, Sosman JA, Chapman PB, Schwartz GK, Craig DW, Carpten JD, Trent JM.

Mol Cancer Ther. 2015 Aug;14(8):1962-71. doi: 10.1158/1535-7163.MCT-15-0153. Epub 2015 Jun 10.

29.

Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression.

Puzanov I, Amaravadi RK, McArthur GA, Flaherty KT, Chapman PB, Sosman JA, Ribas A, Shackleton M, Hwu P, Chmielowski B, Nolop KB, Lin PS, Kim KB.

Eur J Cancer. 2015 Jul;51(11):1435-43. doi: 10.1016/j.ejca.2015.04.010. Epub 2015 May 13.

30.

A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.

Harding JJ, Catalanotti F, Munhoz RR, Cheng DT, Yaqubie A, Kelly N, McDermott GC, Kersellius R, Merghoub T, Lacouture ME, Carvajal RD, Panageas KS, Berger MF, Rosen N, Solit DB, Chapman PB.

Oncologist. 2015 Jul;20(7):789-97. doi: 10.1634/theoncologist.2014-0012. Epub 2015 May 8.

31.

Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation.

Papaspyridonos M, Matei I, Huang Y, do Rosario Andre M, Brazier-Mitouart H, Waite JC, Chan AS, Kalter J, Ramos I, Wu Q, Williams C, Wolchok JD, Chapman PB, Peinado H, Anandasabapathy N, Ocean AJ, Kaplan RN, Greenfield JP, Bromberg J, Skokos D, Lyden D.

Nat Commun. 2015 Apr 29;6:6840. doi: 10.1038/ncomms7840.

32.

Rapid eradication of a bulky melanoma mass with one dose of immunotherapy.

Chapman PB, D'Angelo SP, Wolchok JD.

N Engl J Med. 2015 May 21;372(21):2073-4. doi: 10.1056/NEJMc1501894. Epub 2015 Apr 20. No abstract available.

33.

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.

Carvajal RD, Lawrence DP, Weber JS, Gajewski TF, Gonzalez R, Lutzky J, O'Day SJ, Hamid O, Wolchok JD, Chapman PB, Sullivan RJ, Teitcher JB, Ramaiya N, Giobbie-Hurder A, Antonescu CR, Heinrich MC, Bastian BC, Corless CL, Fletcher JA, Hodi FS.

Clin Cancer Res. 2015 May 15;21(10):2289-96. doi: 10.1158/1078-0432.CCR-14-1630. Epub 2015 Feb 18.

34.

Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged.

Chapman PB, Solit DB, Rosen N.

Cancer Cell. 2014 Nov 10;26(5):603-4. doi: 10.1016/j.ccell.2014.10.017. Epub 2014 Nov 10.

35.

Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients.

Belum VR, Rosen AC, Jaimes N, Dranitsaris G, Pulitzer MP, Busam KJ, Marghoob AA, Carvajal RD, Chapman PB, Lacouture ME.

Cancer. 2015 Jan 1;121(1):60-8. doi: 10.1002/cncr.28980. Epub 2014 Sep 3.

36.

Entzündliches metastasiertes Melanom manifestiert sich als Exanthem in der Leiste einer älteren Frau.

Jedrych J, Chapman PB, Pulitzer M.

J Dtsch Dermatol Ges. 2014 Aug;12(8):726-728. doi: 10.1111/ddg.12327_suppl. German. No abstract available.

PMID:
28349634
37.

Opportunistic infections in patients treated with immunotherapy for cancer.

Kyi C, Hellmann MD, Wolchok JD, Chapman PB, Postow MA.

J Immunother Cancer. 2014 Jun 18;2:19. doi: 10.1186/2051-1426-2-19. eCollection 2014.

38.

Inflammatory metastatic melanoma presenting as a rash in the groin of an elderly woman.

Jedrych J, Chapman PB, Pulitzer M.

J Dtsch Dermatol Ges. 2014 Aug;12(8):726-7. doi: 10.1111/ddg.12327. Epub 2014 Jul 1. No abstract available.

PMID:
24981834
39.

Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.

Carvajal RD, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Kudchadkar RR, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, Doyle A, Ancell K, Panageas KS, Bluth M, Hedvat C, Erinjeri J, Ambrosini G, Marr B, Abramson DH, Dickson MA, Wolchok JD, Chapman PB, Schwartz GK.

JAMA. 2014 Jun 18;311(23):2397-405. doi: 10.1001/jama.2014.6096.

40.

Frontline approach to metastatic BRAF-mutant melanoma diagnosis, molecular evaluation, and treatment choice.

Chapman PB, Hauschild A, Sondak VK.

Am Soc Clin Oncol Educ Book. 2014:e412-21. doi: 10.14694/EdBook_AM.2014.34.e412. Review.

41.

Treating metastatic melanoma in 2014: what just happened and what is next?

Chapman PB.

Am Soc Clin Oncol Educ Book. 2014:16-9. doi: 10.14694/EdBook_AM.2014.34.16. Review.

42.

Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.

Abdel-Wahab O, Klimek VM, Gaskell AA, Viale A, Cheng D, Kim E, Rampal R, Bluth M, Harding JJ, Callahan MK, Merghoub T, Berger MF, Solit DB, Rosen N, Levine RL, Chapman PB.

Cancer Discov. 2014 May;4(5):538-45. doi: 10.1158/2159-8290.CD-13-1038. Epub 2014 Mar 3.

43.

Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.

Nissan MH, Pratilas CA, Jones AM, Ramirez R, Won H, Liu C, Tiwari S, Kong L, Hanrahan AJ, Yao Z, Merghoub T, Ribas A, Chapman PB, Yaeger R, Taylor BS, Schultz N, Berger MF, Rosen N, Solit DB.

Cancer Res. 2014 Apr 15;74(8):2340-50. doi: 10.1158/0008-5472.CAN-13-2625. Epub 2014 Feb 27.

44.

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.

McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbé C, Jouary T, Schadendorf D, O'Day SJ, Kirkwood JM, Eggermont AM, Dréno B, Sosman JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild A.

Lancet Oncol. 2014 Mar;15(3):323-32. doi: 10.1016/S1470-2045(14)70012-9. Epub 2014 Feb 7.

45.

Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy.

Harding JJ, Barker CA, Carvajal RD, Wolchok JD, Chapman PB, Lacouture ME.

J Clin Oncol. 2014 May 10;32(14):e54-6. doi: 10.1200/JCO.2013.49.3528. Epub 2014 Jan 27. No abstract available.

46.

A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.

Flaherty L, Hamid O, Linette G, Schuchter L, Hallmeyer S, Gonzalez R, Cowey CL, Pavlick A, Kudrik F, Curti B, Lawson D, Chapman PB, Margolin K, Ribas A, McDermott D, Flaherty K, Cranmer L, Hodi FS, Day BM, Linke R, Hainsworth J.

Cancer J. 2014 Jan-Feb;20(1):18-24. doi: 10.1097/PPO.0000000000000024.

47.

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.

Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, Giobbie-Hurder A, Lawrence DP, Ibrahim N, Ott PA, Flaherty KT, Sullivan RJ, Harding JJ, D'Angelo S, Dickson M, Schwartz GK, Chapman PB, Wolchok JD, Hodi FS, Carvajal RD.

Cancer. 2013 Oct 15;119(20):3687-95. doi: 10.1002/cncr.28282. Epub 2013 Aug 2.

48.

Dynamic prognostication using conditional survival estimates.

Zabor EC, Gonen M, Chapman PB, Panageas KS.

Cancer. 2013 Oct 15;119(20):3589-92. doi: 10.1002/cncr.28273. Epub 2013 Aug 1.

49.

Evolutionary dynamics of cancer in response to targeted combination therapy.

Bozic I, Reiter JG, Allen B, Antal T, Chatterjee K, Shah P, Moon YS, Yaqubie A, Kelly N, Le DT, Lipson EJ, Chapman PB, Diaz LA Jr, Vogelstein B, Nowak MA.

Elife. 2013 Jun 25;2:e00747. doi: 10.7554/eLife.00747.

50.

Ipilimumab for patients with advanced mucosal melanoma.

Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, Callahan MK, Harding JJ, D'Angelo SP, Dickson MA, Schwartz GK, Chapman PB, Gnjatic S, Wolchok JD, Hodi FS, Carvajal RD.

Oncologist. 2013 Jun;18(6):726-32. doi: 10.1634/theoncologist.2012-0464. Epub 2013 May 28.

Supplemental Content

Loading ...
Support Center